Coastline Trust Co Buys 1,379 Shares of Zoetis Inc. (NYSE:ZTS)

Coastline Trust Co grew its stake in shares of Zoetis Inc. (NYSE:ZTSFree Report) by 30.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 5,926 shares of the company’s stock after acquiring an additional 1,379 shares during the period. Coastline Trust Co’s holdings in Zoetis were worth $1,170,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Stonegate Investment Group LLC raised its stake in Zoetis by 13.3% in the 4th quarter. Stonegate Investment Group LLC now owns 2,389 shares of the company’s stock worth $472,000 after acquiring an additional 280 shares during the last quarter. Builder Investment Group Inc. ADV purchased a new position in Zoetis in the 4th quarter worth $202,000. Pinnacle Financial Partners Inc raised its stake in Zoetis by 15.0% in the 4th quarter. Pinnacle Financial Partners Inc now owns 3,399 shares of the company’s stock worth $671,000 after acquiring an additional 443 shares during the last quarter. Prio Wealth Limited Partnership raised its stake in Zoetis by 3.1% in the 4th quarter. Prio Wealth Limited Partnership now owns 92,677 shares of the company’s stock worth $18,292,000 after acquiring an additional 2,824 shares during the last quarter. Finally, Country Club Bank GFN raised its stake in Zoetis by 1.7% in the 4th quarter. Country Club Bank GFN now owns 5,437 shares of the company’s stock worth $1,072,000 after acquiring an additional 90 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of Zoetis stock opened at $165.01 on Wednesday. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a twelve month low of $151.03 and a twelve month high of $201.92. The business has a 50-day moving average price of $184.62 and a 200 day moving average price of $181.88. The firm has a market cap of $75.47 billion, a PE ratio of 32.55, a P/E/G ratio of 2.55 and a beta of 0.85.

Zoetis (NYSE:ZTSGet Free Report) last announced its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The business had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.19 billion. During the same quarter in the prior year, the firm earned $1.15 EPS. Zoetis’s revenue for the quarter was up 8.5% on a year-over-year basis. Sell-side analysts predict that Zoetis Inc. will post 5.8 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be issued a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 1.05%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s payout ratio is 34.12%.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction dated Thursday, January 18th. The stock was sold at an average price of $191.43, for a total value of $176,689.89. Following the sale, the executive vice president now directly owns 17,569 shares in the company, valued at approximately $3,363,233.67. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last three months, insiders have sold 2,209 shares of company stock worth $408,453. Insiders own 0.15% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Piper Sandler lifted their price objective on Zoetis from $215.00 to $220.00 and gave the company an “overweight” rating in a research note on Tuesday, February 20th. BNP Paribas assumed coverage on Zoetis in a research note on Thursday, December 7th. They set an “outperform” rating and a $237.00 price objective for the company. Jefferies Financial Group reiterated a “buy” rating and set a $230.00 price objective on shares of Zoetis in a research note on Tuesday, December 19th. Finally, Stifel Nicolaus reduced their price objective on Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a research note on Tuesday. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $222.11.

Check Out Our Latest Report on ZTS

Zoetis Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Recommended Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.